Literature DB >> 27940481

Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters.

Bin Dong1, Mark Young2, Xueqing Liu2, Amar Bahadur Singh1, Jingwen Liu3.   

Abstract

The farnesoid X receptor (FXR) plays critical roles in plasma cholesterol metabolism, in particular HDL-cholesterol (HDL-C) homeostasis. Obeticholic acid (OCA) is a FXR agonist being developed for treating various chronic liver diseases. Previous studies reported inconsistent effects of OCA on regulating plasma cholesterol levels in different animal models and in different patient populations. The mechanisms underlying its divergent effects have not yet been thoroughly investigated. The scavenger receptor class B type I (SR-BI) is a FXR-modulated gene and the major receptor for HDL-C. We investigated the effects of OCA on hepatic SR-BI expression and correlated such effects with plasma HDL-C levels and hepatic cholesterol efflux in hyperlipidemic hamsters. We demonstrated that OCA induced a time-dependent reduction in serum HDL-C levels after 14 days of treatment, which was accompanied by a significant reduction of liver cholesterol content and increases in fecal cholesterol in OCA-treated hamsters. Importantly, hepatic SR-BI mRNA and protein levels in hamsters were increased to 1.9- and 1.8-fold of control by OCA treatment. Further investigations in normolipidemic hamsters did not reveal OCA-induced changes in serum HDL-C levels or hepatic SR-BI expression. We conclude that OCA reduces plasma HDL-C levels and promotes transhepatic cholesterol efflux in hyperlipidemic hamsters via a mechanism involving upregulation of hepatic SR-BI.

Entities:  

Keywords:  farnesoid X receptor; hepatocyte nuclear factor 4 α; high density lipoprotein cholesterol; low density lipoprotein receptor; scavenger receptor class B type I; sterol regulatory element-binding protein 2

Mesh:

Substances:

Year:  2016        PMID: 27940481      PMCID: PMC5282951          DOI: 10.1194/jlr.M070888

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  51 in total

1.  High-fructose diet downregulates long-chain acyl-CoA synthetase 3 expression in liver of hamsters via impairing LXR/RXR signaling pathway.

Authors:  Bin Dong; Chin Fung Kelvin Kan; Amar B Singh; Jingwen Liu
Journal:  J Lipid Res       Date:  2013-02-20       Impact factor: 5.922

Review 2.  Molecular biology of PCSK9: its role in LDL metabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  Trends Biochem Sci       Date:  2007-01-09       Impact factor: 13.807

3.  Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels.

Authors:  K F Kozarsky; M H Donahee; A Rigotti; S N Iqbal; E R Edelman; M Krieger
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

4.  Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells.

Authors:  Aiqin Cao; Minhao Wu; Hai Li; Jingwen Liu
Journal:  J Lipid Res       Date:  2010-12-31       Impact factor: 5.922

Review 5.  Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR.

Authors:  Anna C Calkin; Peter Tontonoz
Journal:  Nat Rev Mol Cell Biol       Date:  2012-03-14       Impact factor: 94.444

Review 6.  Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.

Authors:  Luciano Adorini; Mark Pruzanski; David Shapiro
Journal:  Drug Discov Today       Date:  2012-05-29       Impact factor: 7.851

7.  Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte.

Authors:  Fan Chao; Wei Gong; Yingru Zheng; Yuan Li; Gang Huang; Min Gao; Jialin Li; Ramalinga Kuruba; Xiang Gao; Song Li; Fengtian He
Journal:  Atherosclerosis       Date:  2010-10-16       Impact factor: 5.162

8.  Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes.

Authors:  Jay D Horton; Nila A Shah; Janet A Warrington; Norma N Anderson; Sahng Wook Park; Michael S Brown; Joseph L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-25       Impact factor: 11.205

9.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Authors:  Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro
Journal:  Gastroenterology       Date:  2013-05-30       Impact factor: 22.682

10.  Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

Authors:  Gideon M Hirschfield; Andrew Mason; Velimir Luketic; Keith Lindor; Stuart C Gordon; Marlyn Mayo; Kris V Kowdley; Catherine Vincent; Henry C Bodhenheimer; Albert Parés; Michael Trauner; Hanns-Ulrich Marschall; Luciano Adorini; Cathi Sciacca; Tessa Beecher-Jones; Erin Castelloe; Olaf Böhm; David Shapiro
Journal:  Gastroenterology       Date:  2014-12-11       Impact factor: 22.682

View more
  8 in total

1.  Liver-specific knockdown of long-chain acyl-CoA synthetase 4 reveals its key role in VLDL-TG metabolism and phospholipid synthesis in mice fed a high-fat diet.

Authors:  Amar B Singh; Chin Fung K Kan; Fredric B Kraemer; Raymond A Sobel; Jingwen Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-02-05       Impact factor: 4.310

2.  Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice.

Authors:  Chuangzhen Lin; Bingqing Yu; Lixin Chen; Zhaohui Zhang; Weixiang Ye; Hui Zhong; Wenke Bai; Yuping Yang; Biao Nie
Journal:  Front Pharmacol       Date:  2022-05-09       Impact factor: 5.988

3.  FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver.

Authors:  Romeo Papazyan; Xueqing Liu; Jingwen Liu; Bin Dong; Emily M Plummer; Ronald D Lewis; Jonathan D Roth; Mark A Young
Journal:  J Lipid Res       Date:  2018-03-20       Impact factor: 5.922

4.  Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.

Authors:  Amar Bahadur Singh; Bin Dong; Fredric B Kraemer; Yanyong Xu; Yanqiao Zhang; Jingwen Liu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

Review 5.  Bile acids at the cross-roads of gut microbiome-host cardiometabolic interactions.

Authors:  Paul M Ryan; Catherine Stanton; Noel M Caplice
Journal:  Diabetol Metab Syndr       Date:  2017-12-28       Impact factor: 3.320

6.  Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR.

Authors:  Bin Dong; Amar B Singh; Grace L Guo; Mark Young; Jingwen Liu
Journal:  Int J Mol Med       Date:  2019-03-18       Impact factor: 4.101

Review 7.  Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles.

Authors:  Boyan Zhang; Folkert Kuipers; Jan Freark de Boer; Jan Albert Kuivenhoven
Journal:  J Clin Med       Date:  2021-12-21       Impact factor: 4.241

8.  FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR-B1-deficient mice fed a high-fat and high-cholesterol diet.

Authors:  Amar B Singh; Bin Dong; Fredric B Kraemer; Jingwen Liu
Journal:  Physiol Rep       Date:  2020-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.